Anti-Hypertensive Drugs - Kyrgyzstan

Kyrgyzstan

The Anti-Hypertensive Drugs market in Kyrgyzstan is projected to achieve a revenue of US$1.03m by 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of -0.59%, leading to a market volume of US$1.00m by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue of US$12,290.00m in 2024.
Kyrgyzstan's market for anti-hypertensive drugs is witnessing a surge in demand due to the rising prevalence of hypertension among its population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

Kyrgyzstan, a landlocked country in Central Asia, has been witnessing a steady growth in the Anti-Hypertensive Drugs market.

Customer preferences: The demand for Anti-Hypertensive Drugs in Kyrgyzstan is primarily driven by the increasing prevalence of hypertension among the population. According to the World Health Organization (WHO), hypertension affects more than 30% of the adult population in Kyrgyzstan. As a result, there is a growing need for effective and affordable drugs to manage the condition.

Trends in the market: The Anti-Hypertensive Drugs market in Kyrgyzstan is dominated by generic drugs. This is due to the fact that generic drugs are more affordable than their branded counterparts and are easily accessible to the general population. Additionally, the government has been taking steps to promote the use of generic drugs in the country, which has further boosted their popularity.

Local special circumstances: One of the unique challenges in Kyrgyzstan is the lack of access to healthcare facilities in remote areas of the country. This has led to a growing trend of self-medication among the population, which has further increased the demand for over-the-counter (OTC) Anti-Hypertensive Drugs. However, this trend has also raised concerns about the safety and efficacy of these drugs.

Underlying macroeconomic factors: Kyrgyzstan has been experiencing steady economic growth over the past few years, which has led to an increase in disposable income among the population. This has resulted in a growing demand for healthcare services, including Anti-Hypertensive Drugs. Additionally, the government has been investing in healthcare infrastructure and has been taking steps to improve access to healthcare services in the country. These factors are expected to continue to drive the growth of the Anti-Hypertensive Drugs market in Kyrgyzstan in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.